# Preclinical data on Caliway's localized fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies were presented in an oral presentation at the European Congress on Obesity 2026 (ECO 2026) on May 14.

*biotech · news · 2026-05-19 · The Manila Times*

## Key points

- CBL-514 combined with semaglutide increased body weight reduction by 91.5% versus semaglutide alone in animals.
- CBL-514 plus tirzepatide halved post-discontinuation weight regain compared to tirzepatide monotherapy in animal studies.
- CBL-514 combinations produced 182.5% more subcutaneous and 367.4% more visceral fat reduction post-therapy.
- This was the first public disclosure of CBL-514 improving liver lipid and cholesterol indicators in animal models.

**Companies:** Caliway Biopharmaceuticals
**Countries:** Taiwan, Türkiye

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/19/tmt-newswire/pr-newswire/caliway-makes-first-eco-2026-oral-presentation-on-preclinical-data-of-cbl-514-in-combination-with-glp-1r-based-weight-loss-therapies-attracting-strong-interest-from-international-experts-and-global-pharmaceutical-companies-for-its-systemic-metabolic-effects/2346761)

---

Canonical: https://newsio.io/n/b35a9a87-5fdf-4c57-8569-652045d592cf/preclinical-data-on-caliways-localized-fat-reduction-drug-candidate-cbl-514-in-c
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works